P. Seeldrayers

发表

Multiple sclerosis registries in Europe - An updated mapping survey.

M. Trojano, S. Vukusic, T. Ziemssen, 2019, Multiple sclerosis and related disorders.

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

David K Howse, A. Verier, M. Valis, 2018, Multiple sclerosis and related disorders.

The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation

H. Weiner, P. Seeldrayers, David Johnson, 1988, Brain Research.

Rhythmic cortical and muscle discharges induced by fatigue in corticobasal degeneration

M. Manto, S. Goldman, P. Bogaert, 2000, Clinical Neurophysiology.

Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management

B. Decallonne, M. D’haeseleer, V. Delvaux, 2018, Acta Neurologica Belgica.

Short communication A unique episode of REM sleep behavior disorder triggered during surgery for Parkinson's disease

E. Godaux, B. Vanderkelen, J. Jacquy, 2007 .

An Analysis of Mast Cell Frequency in the Rodent Nervous System: Numbers Vary between Different Strains and Can Be Reconstituted in Mast Cell‐Deficient Mice

P. Seeldrayers, David Johnson, D. Yasui, 1991, Journal of neuropathology and experimental neurology.

Astrocytes support mast cell viability in vitro

L. Levin, P. Seeldrayers, David Johnson, 1992, Journal of Neuroimmunology.

Treatment of neoplastic meningitis.

J. Hildebrand, P. Seeldrayers, Jerzy Hildebrand, 1984, European journal of cancer & clinical oncology.

Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis

G. Nagels, M. Heerings, J. Debruyne, 2013, Clinical Neurology and Neurosurgery.

CSF levels of neurotransmitters in Alzheimer‐type dementia. Effects of ergoloid mesylate

O. Dalesio, P. Seeldrayers, D. Desmedt, 1985, Acta neurologica Scandinavica.

Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis

A. Haase, H. Hartung, S. Morrissey, 1993, Journal of Neuroimmunology.

Treatment of experimental allergic neuritis with nedocromil sodium

H. Weiner, P. Seeldrayers, David Johnson, 1989, Journal of Neuroimmunology.

Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program

C. Sindic, J. Debruyne, M. D'hooghe, 2014, Acta Neurologica Belgica.

Role of Mast Cells in Peripheral Nervous System Demyelination

H. Weiner, P. Seeldrayers, D. Johnson, 1988, Annals of the New York Academy of Sciences.

Is the Nociception Coma Scale-Revised a Useful Clinical Tool for Managing Pain in Patients With Disorders of Consciousness?

Steven Laureys, C. Schnakers, C. Chatelle, 2016, The Clinical journal of pain.

Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study.

G. Nagels, D. Langdon, M. D'hooghe, 2017, Multiple sclerosis and related disorders.

Effects of the oral form of ondansetron on cerebellar dysfunction

M. Manto, J. C. Bier, J. Hildebrand, 2003, Journal of Neurology.

123I-ioflupane SPECT scan in a patient with Creutzfeldt-Jakob disease.

P. Seeldrayers, J. Vanderheyden, R. Mazzoleni, 2010, Acta Neurologica Belgica.

Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis

M. Pandolfo, R. Laaksonen, D. Lütjohann, 2008, European Journal of Human Genetics.

Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management

B. Decallonne, M. D’haeseleer, V. Delvaux, 2018, Acta Neurologica Belgica.

Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: Correlation with magnetic resonance imaging

H. Hartung, K. Toyka, K. Reiners, 1995, Annals of neurology.

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

Marco Rovaris, Massimo Filippi, Frederik Barkhof, 2001, The Lancet.

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial

A. Michotte, C. Sindic, M. D'hooghe, 2010, Multiple sclerosis.

Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program

C. Sindic, J. Debruyne, M. D'hooghe, 2014, Acta Neurologica Belgica.

Reversible capsulo-tegmental locked-in state as first manifestation of multiple sclerosis

S. Borenstein, P. Seeldrayers, J. Flament-Durand, 1987, Journal of Neurological Sciences.

Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data

A. Compston, A. Thompson, L. Kappos, 2001, Multiple sclerosis.

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Alexander Parajeles Vindas, P. Kowey, D. Arnold, 2016, Neurology. Clinical practice.

The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources.

L. Leocani, W. van Hecke, M. Tintoré, 2021, International journal of MS care.

CBM 36‐733 (2‐Methyl‐alpha‐ergokryptine) In primary degenerative dementia: Results of a european multicentre trial

J. Orgogozo, M. Philpot, W. Danielczyk, 1988 .

Soluble ICAM‐1 serum levels in multiple sclerosis and viral encephalitis

H. Hartung, K. Toyka, K. Reiners, 1993, Neurology.

A unique episode of REM sleep behavior disorder triggered during surgery for Parkinson's disease

E. Godaux, B. Vanderkelen, J. Jacquy, 2007, Journal of the Neurological Sciences.